0000000000366156

AUTHOR

Giuseppe Boriani

0000-0002-9820-4815

showing 4 related works from this author

Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF General Long-Term Reg…

2019

Aims In recent years, stroke prevention in patients with atrial fibrillation (AF) has radically changed, with increasing use of non-vitamin K antagonist oral anticoagulants (NOACs). Contemporary European data on AF thromboprophylaxis are needed. Methods and results We report 1-year follow-up data from the EURObservational Research Programme in Atrial Fibrillation (EORP-AF) General Long-Term Registry. Outcomes were assessed according to antithrombotic therapy. At 1-year follow-up, 9663 (88.0%) patients had available data for analysis: 586 (6.1%) were not treated with any antithrombotic; 681 (7.0%) with antiplatelets only; 4066 (42.1%) with vitamin K antagonist (VKA) only; 3167 (32.8%) with …

AdultMaleAcute coronary syndromemedicine.medical_specialtymedicine.drug_classHemorrhageOutcomes030204 cardiovascular system & hematologyLower riskRisk Assessment[SHS]Humanities and Social Sciences03 medical and health sciences0302 clinical medicineFibrinolytic AgentsRisk FactorsPhysiology (medical)Internal medicineCause of DeathAntithromboticMedicineHumans030212 general & internal medicineProspective StudiesRegistriesPractice Patterns Physicians'StrokeAgedEORP-AF registryAged 80 and overAntithrombotic therapybusiness.industryProportional hazards modelAtrial fibrillationVitamin K antagonistMiddle Agedmedicine.diseaseAtrial fibrillationObservational registriesEuropeStrokeFemaleCardiology and Cardiovascular MedicinebusinessAntithrombotic therapy; Atrial fibrillation; EORP-AF registry; Observational registries; Outcomes; StrokeFibrinolytic agentFollow-Up Studies
researchProduct

Rate vs. rhythm control and adverse outcomes among European patients with atrial fibrillation

2018

Aim The impact of rate and rhythm control strategies on outcomes in patients with atrial fibrillation (AF) remains controversial. Our aims were: to report use of rate and rhythm control strategies in European patients from the EURObservational Research Program AF General Pilot Registry. Secondly, to evaluate outcomes according to assigned strategies. ........................................................................................................................................................... Methods and results Use of pure rate and rhythm control agents was described according to European regions. 1-year follow-up data were reported. Among rate control strategies, beta-blockers …

MaleTime FactorsRate controlAction PotentialsPilot Projects030204 cardiovascular system & hematologyAmiodaroneAction Potentials/drug effectsHeart Conduction System/drug effectsCardiologists0302 clinical medicineHeart RateRisk FactorsCause of DeathAtrial Fibrillation030212 general & internal medicineRegistriesPractice Patterns Physicians'Cause of deathAged 80 and overAll-cause death; Atrial fibrillation; Major adverse events; Rate control; Registry; Rhythm controlHeart Rate/drug effectsAtrial fibrillationMiddle AgedEuropeTreatment OutcomeCohortCardiologyHealthcare Disparities/trendsRhythm controlFemaleCardiology and Cardiovascular MedicineAnti-Arrhythmia AgentsCardiologists/trendsmedicine.drugmedicine.medical_specialtyMajor adverse eventsRegistryAll-cause deathAnti-Arrhythmia Agents/adverse effectsEurope/epidemiology03 medical and health sciencesHeart Conduction SystemPhysiology (medical)Internal medicineHeart ratemedicineAtrial Fibrillation/diagnosisHumansHealthcare DisparitiesAdverse effectAgedbusiness.industryProportional hazards modelmedicine.diseaseAtrial fibrillationPractice Patterns Physicians'/trendsAtrial fibrillation • Rate control • Rhythm control • Major adverse events • All-cause death • RegistryPropensity score matchingbusiness
researchProduct

Detect Long-term Complications After ICD Replacement (DECODE): Rationale and Study Design of a Multicenter Italian Registry

2015

The replacement of implantable cardioverter-defibrillators (ICDs) may give rise to considerable clinical consequences, the importance of which is underrated by the medical community. Replacement-related adverse events are difficult to identify and require monitoring of both short-term complications and long-term patient outcome. The aim of this study is to perform a structured evaluation of both short- and long-term adverse events and a cost analysis of consecutive ICD replacement procedures. Detect Long-term Complications After ICD Replacement (DECODE) is a prospective, single-arm, multicenter cohort study designed to estimate long-term complication rates (at 12 months and 5 years) in pati…

Research designmedicine.medical_specialtyCost–benefit analysisbusiness.industryMEDLINEGeneral Medicinemedicine.diseaseHealth caremedicineMedical emergencyCardiology and Cardiovascular MedicineAdverse effectProspective cohort studyRisk assessmentbusinessIntensive care medicineCohort studyClinical Cardiology
researchProduct

Additional file 1 of Impact of clinical phenotypes on management and outcomes in European atrial fibrillation patients: a report from the ESC-EHRA EU…

2021

Additional file 1 : Table S1. Use of Antithrombotic drugs according to Patient Clusters in patients with High Thromboembolic Risk. STROBE Checklist. Appendix. EURObservational Research Programme Atrial Fibrillation (EORP-AF) Long-Term General Registry Committees and Investigators.

researchProduct